

Biacore references

Biotherapeutics

Review

- *Danlin Yang, Ajit Singh, Helen Wu, Rachel Kroe-Barret. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. *Anal. Biochemistry*. 2016; 508; 78–96.
- *Karlsson R. Biosensor binding data and its applicability to the determination of active concentration. 2016; Oct; Online; <http://rd.springer.com/article/10.1007/s12551-016-0219-5>.
- Federici M, Lubiniecki A, Manikwar P, Volkin D.B. Analytical lessons learned from selected therapeutic protein drug comparability studies. *Biologicals*. 2013; 41; 131-147.
- Shih H.H. Discovery Process for Antibody-Based Therapeutics (Chapter 2). M. A. Tabrizi et al. (eds.). *Development of Antibody-Based Therapeutics*. 2012; doi: 10.1007/978-1-4419-5955-3_2.

Antibody screening

- Vincent KJ, Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. *Biotechnol J*. 2012; 7(12):1444-50.
- Hearty S, Leonard P, O'Kennedy R. Measuring antibody-antigen binding kinetics using surface plasmon resonance. *Methods Mol Biol*. 2012; 907:411-42.
- Schräml M, von Proff L. Temperature-dependent antibody kinetics as a tool in antibody lead selection. *Methods Mol Biol*. 2012; 901:183-94.
- Schräml M, Biehl M. Kinetic screening in the antibody development process. *Methods Mol Biol*. 2012; 901:171-81.

Tight binders

- Katsamba P.S. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. *Analytical Biochemistr*. 2006; 352:208–221.



Novel antibody formats

- Gassner C, Lipsmeier F, Metzger P, Beck H, Schnueriger A, Regula J.T, Moelleken J. Development and validation of a novel SPR-based assay principle for bispecific molecules. *Journal of Pharmaceutical and Biomedical Analysis*. 2014; <http://dx.doi.org/10.1016/j.jpba.2014.09.007>.
- Stubenrauch K, Wessels U, Essig U, Vogel R, Waltenberger H, Hansbauer A, Koehler A, Heinrich J. An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab. *Journal of Pharmaceutical and Biomedical Analysis*. 2014; Oct 14; 102C:459-467. doi: 10.1016/j.jpba.2014.10.005.
- Rauscher A, Frindel M, Maillasson M, Le Saëc P, Rajerison H, Gestin J.F, Barbet J, Faivre-Chauvet A, Mouglin-Degraef M. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. *Nucl Med Biol*. 2014 May; 41 Suppl:e66-74. doi: 10.1016/j.nucmedbio.2013.12.012.
- Castoldi R, et al. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. *Protein Engineering, Design & Selection* 2012; 25(10):551-559.
- Bostrom J, Haber L, Koenig P, Kelley R. F, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. *PLoS ONE* 2011; 6(4):e17887. doi:10.1371/journal.pone.0017887.

Epitope analyses

- Lin J.C., Ettinger R.A., Schuman J.T., Zhang A.H., Wamiq-Adhami M, Nguyen P.C., et al. Six Amino Acid Residues in a 1200 Å² Interface Mediate Binding of Factor VIII to an IgG4κ Inhibitory Antibody. 2015; *PLoS ONE* 10(1).
- Nguyen P.C., Lewis K.B., Ettinger R.A., Schuman J.T., Lin J.C., Healey J.F., Meeks S.L., Lollar P., Pratt K.P. High-resolution mapping of epitopes on the C2 domain of Factor VIII by analysis of Point Mutants Using Surface Plasmon Resonance. *Blood*. 2014; 123(17) 2732-9.
- Abdiche Y. N, Malashock D. S, Pinkerton A, Pons J. Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. *Anal Biochem*. 2009; Mar15; 386(2):172-80. doi: 10.1016/j.ab.2008.11.038. Epub 2008 Dec 7.
- Abdiche Y. N, Malashock D. S, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. *Protein Sci*. 2008; Aug17(8):1326-35. doi: 10.1110/ps.035402.108. Epub 2008 May27.

Comparison with Elisa

- Heinrich L, Tissot N, Hartmann D. J, Cohen R. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. *J Immunol Methods*. 2010; Jan31; 352(1-2):13-22.



FcRI binding analysis

- *Kiyoshi M, Caaveiro J, Kawai T, Tashiro S, Ide T, Asaoka Y, Hatayama K, Tsumoto K. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. *Nature communications*. 2015; April; 6;6866. doi: 10.1038/ncomms7866.

FcRn binding analysis

- Abdiche Y.N, Yeung Y.A, Chaparro-Riggers J, Barman I, Strop P, Chin S.M, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. *mAbs*. 2015; 7:2, 331-343.
- Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, Hertenberge rH, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. *mAbs*. 2014; 6:5, 1229-1242. doi: 10.4161/mabs.29601.
- Gurbaxani B, Dostalek M, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? *Mol Immunol*. 2013; Dec; 56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug2.
- Kelley R. F, Meng Y. G. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. *Methods Mol Biol*. 2012; 901:277-93. doi: 10.1007/978.1.61779.931.0.18.
- Leonard P, Hayes C. J, O'Kennedy R. Rapid temperature-dependent antibody ranking using Biacore A100. *Anal Biochem*. 2011; Feb15; 409(2):290-2. doi: 10.1016/j.ab.2010.10.036. Epub 2010 Nov2.
- Steukers M, Schaus J. M, van Gool R, Hoyoux A, Richalet P, Sexton D. J, Nixon A. E, Vanhove M. Rapid kinetic-based screening of human Fab fragments. *J Immunol Methods*. 2006; Mar20; 310(1-2):126-35. Epub 2006 Jan31.
- Cooper M. A. Label-free screening of bio-molecular interactions. *Anal Bioanal Chem*. 2003; Nov;377(5):834-42. Epub 2003 Aug7.

FcγR - Review

- Berkowitz S, Engen J, Mazzeo J, Jones G. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. *Nat. Rev. Drug Discovery*. 2012; 11; 527-540.
- Jiang X.R, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. *Nat. Rev. Drug Discovery*,2011;10;101-9.
- Cees E. van der Poel, Robbert M. Spaapen, Jan G. J. van de Winkel, Jeanette H. W. Leusen Functional Characteristics of the High Affinity IgG Receptor, FcγRI. *J Immunol*. 2011; 186; 2699-2704.
- Rieder N, Gazzano-Santoro H, Schenerman M, Strause R, Fuchs C, Mire-Sluis A, McLeod L.D. The roles of bioactivity assays in lot release and stability testing. *BioProcess International*. 2010; June.



FcγR – Fc structure and binding analysis

- *Wessels U, Poehler A, Moheysen-Zadeh M, Zadak M, Staack R, Umana P, Heinrich J, Stubenrauch K, Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I. *Future Science*, October 2016, Vol. 8, No. 20, Pages 2135-2145.
- Hayes J, Frostell A, Cosgrave E, Struwe W, Potter O, Davey G, Karlsson R, Anneren C, Rudd P. Fc gamma Receptor Glycosylation Modulates the Binding of IgG Glycoforms - a Requirement for Stable Antibody Interactions. *Journal of Proteome Research*. 2014; 13; 5471-5485.
- Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinic J, Regula J. T. Cell type specific and site directed N-glycosylation pattern of FcγRIIIa. *Journal of proteome research*. 2013; 10; 3031-3039.
- Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy*. 2013; 2; 495-507.
- Heider K-H, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf G. R, Borges E. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high pro-apoptotic activity for treatment of B-cell malignancies. *Blood*, 2011; 118; 4159-68.
- Hulse J, Cox C. In vitro functional testing methods for monoclonal antibodies. *BioProcess International*. 2013; June.
- Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M. The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation. *Glycobiol*. 2009; 19, 126-34.
- Bruhns P, Iannascoli B, England P, Mancardi D. A, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. *Blood*, 2009; 113; 3716-3725.
- Ferrara C. et al. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. *J. Biol. Chem*. 2006; 281; 5032-5036.
- Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. *Nature*. 2000; 406; 267-273.
- Radaev S, Motyka S, Fridman W. H, Sautes-Fridman C, Sun P. D. The structure of a human type III Fcγ receptor in complex with Fc. *The Journal of biological chemistry*. 2000; 276; 16469-16477.

Kinetics and PK

- *Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. *Nature biotechnology*. 2010; Nov 28; 11. doi:10.1038/nbt.1691.



Reagent qualification

- O'Hara D.M, Theobald V, Egan A.C, Usansky J, Krishna M, TerWee J, Maia M, Spriggs F.P, Kenney J, Safavi A, Keefe J. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. *AAPS Journal*. 2012; 14; 2.
- Staack R.F, Stracke J.O, Stubenrauch K, Vogel R, Schleypen J, Papadimitriou S. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. *Bioanalysis*. 2011; 3(5); 523-534.

Late stage development and comparability

- *Karlsson R et al. Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data. *Analytical Biochemistry*, 2016: 502: 53–63
- *Pol et al. Evaluation of calibration-free concentration analysis provided by Biacore™ systems. *Analytical Biochemistry*. 2016: 510: 88-97
- Federici M, Lubiniecki A, Manikwar P, Volkin D. Analytical lessons learned from selected therapeutic protein drug comparability Studies. *Biologicals*. 2013; 4; 131-147.
- *Rosie Upton, Leonard Bell, Colin Guy, Paul Caldwell, Sian Estdale, Perdita E. Barran, and David Firth. Orthogonal assessment of Biotherapeutic Glycosylation : A case study correlating N-glycan core glycosylation of Herceptin with mechanism of action. *Analytical Chemistry*. 2016; 88 (20); 10259–10265.

Structure function

- Kling A, Lukat P, Almeida D.V, Bauer A, Fontaine E et al. Targeting DnaN for tuberculosis therapy using novel griselimycins. *Science*. 2015; Jun 5; 348(6239); 1106-12. doi: 10.1126/science.aaa4690.
- Müller M, Hopfner K.P, Witte G. c-di-AMP recognition by Staphylococcus aureus PstA. *FEBS Letter*. 2015; Jan 2; 589(1); 45-51.

Protein – DNA binding

- Rollins M, Schuman J, Paulus K, Bukhari H, Wiedenheft B. Mechanism of foreign DNA recognition by a CRISPR RNA-guided surveillance complex from *Pseudomonas aeruginosa*. *Nucleic Acids Research*. 2015; Feb. doi: 10.1093/nar/lgkv094.
- Groothuizen F, Fish A, Petoukhov M, Reumer A, Manelyte L, Winterwerp H, Marinus M, Lebbink J, Svergun D, Friedhoff P, Sixmadfg T. Using stable MutS dimers and tetramers to quantitatively analyze DNA mismatch recognition and sliding clamp formation. *Nucleic Acids Research*. 2013; 1–16.

Concentration determination and Calibration-Free Concentration Analysis

- *Jonathan Visentin, LaetitiaMinder, Jar-HowLee, Jean-LucTaupin, Carmelo Di Primo. Calibration free concentration analysis by surface plasmon resonance in a capture mode. *Science direct*. 2015; Online
- Frostell Å, Mattsson A, Eriksson Å, Wallby E, Kärnhall J, Illarionova N.B., Estmer Nillson C. Nine surface plasmon resonance assays for specific protein quantitation during cell culture and process development. *Analytical Biochemistry*. 2015; 477; 1–9.



Immunogenicity

- Gibbs E, Karim M.E, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated patients with transient versus sustained NAb. *Clinical Immunol.* 2014; Dec24. Pii:S1521-6616(14)00283-6. doi:10.1016/j.clim.2014.12.005.

Guidelines

- Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. U.S. Department of Health and human services/Food and drug Administration. May 2014.
- Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. U.S. Department of Health and human services/Food and drug Administration. February 2012.
- Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. U.S. Department of Health and human services/Food and drug Administration. February 2012.



Membrane proteins

Review

- Patching S. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. *Biochim Biophys Acta*. 2014; Jan; 1838(1 Pt A); 43-55.
- Chu R, Reczek D, Brondyk W. Capture-stabilize approach for membrane protein SPR assays. *Scientific reports*. 2014; Dec; 4; 7360.

Nanodiscs

- *Bocquet N, Kohler J, Hug M, Kuszniir E, Rufer A, Dawson R, Hennig M, Ruf A, Huber W, Huber S. Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance. *Biochimica et Biophysica Acta*. 2015; 1848; 1224-1233.
- Adamson R, Watts A. Kinetics in the Early events of GPCR signalling. *FEBS Letters*. 2014; xxx; xxx-xxx. *Article in press*.
- Harding P, Hadingham T, McDonnell J, Watts A. Direct analysis of a GPCR-agonist interaction by surface plasmon resonance. *Eur Biophys Journal*. 2006; Oct; 35(8):709-12. *Epub 2006 May 18*.

Liposomes

- *Schillinger A-S, Grauffel C, Khan H, Halskau O, Reuter N. Two homologous neutrophil serine proteases bind to POPC vesicles with different affinities: When aromatic amino acids matter. *Biochimica et Biophysica Acta*. 2014; 1838; 3191-3202.

Membrane targets

- *Takeharu Ogura, Yoshiyuki Tanaka, Hiromu Toyoda. Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. *Analytical Biochemistry*. 2016; Volume 508, 1 September 2016, Pages 73-77.



Vaccines

Review

- Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. *Expert Rev Vaccines*. 2010; Jun; 9(6):645-64.
- Van Regenmortel M. H. Binding measurements as surrogate biological assays: Surface plasmon resonance biosensors for characterizing vaccine components. *Dev Biol*. 2000; 103:69-74.

Research and vaccine development

- *Lianpan Dai et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody; *Cell Host & Microbe*. 2016; Nov; 19, p696-704
- Pissania F, Malherbec D.C, Schuman J.T, Robinse H, Parkc B.S, Shelly J. Krebs, Barnett S.W, Haigwooda N.L. Improvement of antibody responses by HIV envelope DNA and protein co-immunization. *Vaccine*. 2013; <http://dx.doi.org/10.1016/j.vaccine.2013.11.022>.
- Lahoud M.H, Ahmet F, Zhang J-G, Meuterb S, Policheni A.N, Kitsoulisa S, Lee C-N, O'Keeffe M, Sullivan L.C, Brooks A.G, Berry R, Rossjohn J, Mintern J.D, Vega-Ramos J, Villadangos J.A, Nicola n.A, Nussenzweigg M.C, Staceyh K.J, Shortman K, Heath W.R, Caminschia I. DEC-205 is a cell surface receptor for CpG oligonucleotides. *PNAS*. 2012; Oct2; 109(40); 16270-16275.
- Kovacs J.M, Nkololac J.P, Penga H, Cheungc A, Perryc J, Millerc C.A, Seamanc M.S, Barouchc D.H, Bing Chen. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. *PNAS*. 2012; Jul24; 109(20); 12111-12116.
- Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. *Proc Natl Acad Sci U S A*. 2012; Apr 3; 109(14):5229-34.



Process optimization, process control and product stability

- Manin C, Naville S, Gueugnon M, Dupuy M, Bravo de Alba Y, Adam O. Method for the simultaneous assay of the different poliovirus types using surface plasmon resonance technology. *Vaccine*. 2013; 31; 1034–1039.
- Towne V, Zhao Q, Brown M, Finnefrock A.C. Pairwise antibody foot printing using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization. *Journal of Immunological Methods*. 2013; 388; 1-7.
- Mulder A.M, Carragher B, Towne V, Meng Y, Wang Y, Dieter L, Potter C.S, Washabaugh M.W, Sitrin R.D, Zhao Q. Toolbox for Non-Intrusive Structural and Functional Analysis of Recombinant VLP Based Vaccines: A Case Study with Hepatitis B Vaccine. *PLoS ONE*. 2012; 7(4): e33235. doi:10.1371/journal.pone.0033235.
- Westdijk J, Brugmans D, Martin J, van't Oever A, Bakker WM, Levels L, Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines. *Vaccine*. 2011; 29; 3390-3397.
- Zhao Q, Towne V, Brown M, Wang Y, Abraham D, Oswald C.B, Gimenez J.A, Washabaugh M.W, Kennedy R, Sitrin R.D. In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization. *Vaccine*. 2011; 29; 7936–7941.



Small Molecules & Fragments

Review

- *Tim Kaminski, Anders Gunnarsson, and Stefan Geschwindner. Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery. *ACS Publications*; 2016; Dec 15; pubs.acs.org/acssensors; doi: 10.1021/acssensors.6b00735.
- *Jean-Paul Renaud, Chun-wa Chung, U. Helena Danielson, Ursula Egner, Michael Hennig, Roderick E. Hubbard¹ and Herbert Nar; Biophysics in drug discovery: impact, challenges and opportunities. *Nat. Rev. Drug discovery*. 2016; Online
- *Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard, Wolfgang Jahnke and Harren Jhoti. Twenty years on: the impact of fragments on drug discovery. *Nat. Rev. Drug discovery*. 2016; Online
- Andersson K et al. Label-free kinetics binding data as a decisive element in drug discovery. *Expert opinion on drug discovery* 2006; 1:5; 439-446.

Structure kinetic relation

- *Cramer J, Krimmer SG, Fridh V, Wulsdorf T, Karlsson R, Heine A, Klebe G. Elucidating the Origin of Long Residence Time Binding for Inhibitors of the Metalloprotease Thermolysin. *ACS Chem Biol*. 2016; Dec 13; doi:10.1021/acscchembio.6b00979.
- *Krimmer S, Cramer J, Betz M, Fridh V, Karlsson R, Heine A, Klebe G; Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein Bound Ligands. *Journal of Medicinal Chemistry*. 2016; nov; Online <http://link.springer.com/article/10.1007/s12551-016-0219-5>
- Muller M, Hopfner KP, Witte G. c-di-AMP recognition by staphylococcus aureus PstA. *FEBS Letters* 2014. <http://dx.doi.org/10.1016/j.febslet.2014.11.022>.
- Heinrich T, Seenisamy J, Emmanuvel L, Kulkarni S, Bomke J, Rohdich F, Greiner H, Esdar C, Krier M, Grädler U, Musil D. Fragment-based discovery of new highly substituted 1H-Pyrrolo[2,3-b]- and 3H-Imidazo[4,5-b]-Pyridines as focal adhesion kinase inhibitors. *J. Med. Chem*. 2013; 8 jan (web); <http://pubs.acs.org> on January 10, 2013.
- Danielsson H. Integrating surface plasmon biosensor-based interaction kinetic analyses into the lead discovery and optimization process. *Future Med. Chem*. 2009; 1(7).
- Andersson K, Hämmäläinen M. Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects. *Journal of Chemometrics*. 2006; 20: 1-6.
- Markgren P-O et al. Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. *J. Med. Chem*. 2002; 45; 5430-9.



Kinetic and biological function

- *Lei H, Jones C, Zhu T et al. Identification of B. anthracis N5-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. *Bioorganic & Medicinal Chemistry*. 2016; Feb 15;24(4):596-605
- *Alan M Jones, Rob L.M van Montfort. A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms. *Sci Rep*. 2016; Oct; 6:34701
- Segala E, Errey J.C., Fiez-Vandal C, Zhukov A, Cooke R.M. Biosensor-based affinities and binding kinetics of small molecule antagonists to the adenosine A2A receptor reconstituted in HDL-like particles. *FEBS Letters*. 2015; doi: <http://dx.doi.org/10.1016/j.febslet.2015.04.030>.
- Dahl G, Akerud T. Pharmacokinetics and the drug–target residence time concept. *Drug Discovery Today*. 2013; Aug; 18,Numbers 15/16.
- Swinney D.C, Anthony J. How were new medicines discovered? *Nature Reviews Drug Discovery*. 2011; 10; 507-519.
- Tummino P.J, Copeland R.A. Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function. *Biochemistry*. 2008; May20; 47.
- Copeland R.A, Pompliano D.L, Meek T.D. Drug–target residence time and its implications for lead optimization. *Nature Reviews Drug Discovery* | AOP, published online 4 Aug2006.
- Swinney D.C. Biochemical mechanism of drug action: What does it take for success? *Nature Reviews Drug Discovery*. 2004; Sep; 3.

*new reference, added since last version



For local office contact information, visit
www.gelifesciences.com/contact

www.gelifesciences.com/biacore

GE Healthcare UK Limited
Amersham Place
Little Chalfont
Buckinghamshire, HP7 9NA
UK

GE and GE monogram are trademarks of General Electric Company.

Biacore is a trademark of General Electric Company or one of its subsidiaries.

© 2016 General Electric Company – All rights reserved.

First published Oct 2014

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

GE Healthcare UK Ltd
Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp
800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Europe GmbH
Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare Japan Corporation
Sanken Bldg. 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073, Japan

